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DFS = disease-free survival; ER = oestrogen receptor; IHC = immunohistochemistry; mTOR = mammalian target of rapamycin; PI3K = phospho-
inositol-3 kinase.
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Introduction
Mammalian target of rapamycin (mTOR) is a kinase with
sequence homology to phosphoinositol-3 kinase (PI3K). It
is a downstream mediator in the PI3K/AKT pathway,
which regulates proliferation, survival, mobility and
angiogenesis. The targets of mTOR include p70s6 kinase
and 4E-BP1 (for review, see Bjornsti and Houghton [1]).
Rapamycin is an antibiotic and fungicide isolated from
Streptomyces hygroscopicus that inhibits mTOR activity
and has been approved as an immunosuppressive drug in
organ transplant patients. Interest in rapamycin and
analogues as cancer treatments is growing [2] because of
the observation that the PI3K/AKT pathway is often
altered in cancers. This can occur via mutation in the
tumour suppressor gene PTEN, which downregulates the
pathway, or over-expression of receptors (such as HER2)
that stimulate the pathway. It can also occur via over-
expression of other proteins in the pathway (such as
AKT/protein kinase B) due to gene amplification or failure
to break down the proteins.
Rapamycin itself has poor aqueous solubility and is not
stable, and so several analogues (CCI-779, RAD001 and
AP23573) have been developed that are being tested in
clinical trials for cancer treatment. These new drugs can
potentially be used for the treatment of breast cancer
once those patients who will respond to the drug can be
identified. In this review I summarize two recent papers
that provide insight into the determinants of sensitivity to
rapamycin and the potential synergism with conventional
chemotherapies.
Rapamycin and its analogues in breast cancer
Study of breast cancer cell lines has suggested that cells
that express the active (phosphorylated) form of AKT are
sensitive to rapamycin treatment [3], as are those that are
oestrogen receptor (ER) positive, lack PTEN, or over-
express HER2 [4]. This result has been recapitulated in
breast cancer patients, with Chan [4] reporting this year
that patients who responded to CC1-779 in a clinical trial
had lost PTEN expression and/or had HER2 over-
expression. Although that trial was small, including only
109 patients, none of the 32 who were HER2 negative
showed any significant response to treatment.
Two recent papers published in Clinical Cancer Research
[5,6] have tackled the subject of targeting mTOR with
rapamycin in breast cancer. Zhou and coworkers [5]
examined 165 primary breast cancers with antibodies
directed against HER2 and phosphorylated forms of AKT,
mTOR and 4E-BP1 (a downstream target of mTOR). They
compared staining in the primary breast tumours with that
seen in normal breast epithelium, fibroadenoma,
intraductal hyperplasia and ductal carcinoma in situ. They
found that phosphorylation levels of all three molecules
generally increased during the transition from normal
epithelium to invasive disease. None of the fibroadenomas
expressed phosphorylated forms of the markers. Few of
the normal breast samples expressed phosphorylated AKT
(two out of eight with low expression) and phosphorylated
mTOR (one out of eight with high expression), and none
expressed phosphorylated 4E-BP1. The levels observed in
intraductal hyperplasia and ductal carcinoma in situ were
higher than in normal breast epithelium, and this trend
continued with invasive carcinomas. As with in vitro
studies, phosphorylated AKT/mTOR/4E-BP1 was more
common in tumours that over-expressed HER2, and
phosphorylated AKT was positively correlated with ER
expression.
With univariate analysis those investigators also
demonstrated that phosphorylated AKT, mTOR and 4E-
BP1 were associated with differences in disease-free
survival (DFS). Patients whose tumours had high
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phosphorylated mTOR had significantly shorter DFS,
whereas those with low phosphorylated AKT or 4E-BP1
had longer DFS. A multivariate analysis including
conventional prognostic indicators was not presented,
and so it is unclear whether this would add any
information to current prognostic data. In a follow-up to
this tissue-based study, they examined the effect of
rapamycin on HER2-expressing breast cancer cell lines
[5]. They concluded that HER2 over-expression leads to
increased phosphorylated mTOR and phosphorylated 4E-
BP1 expression, and that these cells are sensitive to
rapamycin treatment.
In the same issue of Clinical Cancer Research, Mondesire
and coworkers [6] describe the interaction of rapamycin
and standard chemotherapy agents in breast cancer cell
lines and a xenograft mouse model of breast cancer. They
observed that rapamycin alone resulted in growth
inhibition of sensitive cell lines and that the effect of
rapamycin in combination with paclitaxel, carboplatin and
vinorelbine was synergistic (i.e. the combined effect is
greater than that expected by the addition of the effects of
each drug). Synergism was exhibited by increased growth
inhibition in the case of paclitaxel and increased apoptosis
when rapamycin was combined with both paclitaxel and
carboplatin. These effects were only observed in
rapamycin-sensitive cell lines and not in rapamycin-
insensitive ones. In addition, they found that use of
rapamycin could increase the chemosensitivity of HER2
over-expressing cells that normally show some resistance
to paclitaxel and carboplatin. Finally, they assessed the
efficacy of rapamycin in combination with paclitaxel in
nude mice with cell line xenografts. This experiment
demonstrated that the combination was more effective in
reducing tumour volume than either drug alone.
Conclusion
Both of these papers present evidence that activation of
the AKT/mTOR pathway by HER2 (and possibly by other
receptors such as ER) can lead to sensitivity of breast
cancer cells to rapamycin and its analogues. Zhou and
coworkers [5] showed that the active (phosphorylated)
forms of proteins in the AKT/mTOR pathway can be
detected in paraffin-embedded breast tumours using
immunohistochemistry (IHC) and that the information
provided may have prognostic value. It is also expected to
identify those patients with tumours that are sensitive to
rapamycin and its analogues. In addition, the results
presented by Mondesire and coworkers [6] suggest that,
in those patients whose tumours are sensitive to
rapamycin (or its analogues), the combination with
conventional chemotherapy may have an even greater
effect. However, it is not certain that phosphorylated forms
of proteins can accurately and reliably be detected using
conventional IHC on paraffin-embedded tissue. In a recent
meeting presentation [7], concern was expressed that
delayed fixation of samples could affect phosphorylation
status of proteins and thus their detection.
In conclusion, these findings show promise that patients
who will benefit from treatment with rapamycin or its
analogues can be identified with IHC using antibodies
against phosphorylated proteins. However, further work in
this field is required to determine which target(s) are most
useful for determining sensitivity and whether IHC is the
best method to detect them.
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